- Home
- IHRT vs AKBA Comparison
IHRT vs AKBA Comparison
Compare IHRT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHRT
- AKBA
- Stock Information
- Founded
- IHRT N/A
- AKBA 2007
- Country
- IHRT United States
- AKBA United States
- Employees
- IHRT N/A
- AKBA N/A
- Industry
- IHRT Broadcasting
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- IHRT Consumer Discretionary
- AKBA Health Care
- Exchange
- IHRT Nasdaq
- AKBA Nasdaq
- Market Cap
- IHRT 296.6M
- AKBA 336.2M
- IPO Year
- IHRT 2019
- AKBA 2014
- Fundamental
- Price
- IHRT $2.40
- AKBA $1.88
- Analyst Decision
- IHRT Buy
- AKBA Strong Buy
- Analyst Count
- IHRT 3
- AKBA 2
- Target Price
- IHRT $3.00
- AKBA $5.75
- AVG Volume (30 Days)
- IHRT 1.3M
- AKBA 2.4M
- Earning Date
- IHRT 11-07-2024
- AKBA 11-07-2024
- Dividend Yield
- IHRT N/A
- AKBA N/A
- EPS Growth
- IHRT N/A
- AKBA N/A
- EPS
- IHRT N/A
- AKBA N/A
- Revenue
- IHRT $3,803,046,000.00
- AKBA $169,879,000.00
- Revenue This Year
- IHRT $6.56
- AKBA N/A
- Revenue Next Year
- IHRT N/A
- AKBA $6.13
- P/E Ratio
- IHRT N/A
- AKBA N/A
- Revenue Growth
- IHRT N/A
- AKBA N/A
- 52 Week Low
- IHRT $0.81
- AKBA $0.80
- 52 Week High
- IHRT $3.12
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- IHRT 59.51
- AKBA 61.05
- Support Level
- IHRT $2.24
- AKBA $1.75
- Resistance Level
- IHRT $2.50
- AKBA $2.02
- Average True Range (ATR)
- IHRT 0.24
- AKBA 0.11
- MACD
- IHRT 0.01
- AKBA -0.02
- Stochastic Oscillator
- IHRT 62.23
- AKBA 60.00
About IHRT iHeartMedia Inc.
iHeartMedia Inc is a United States-based diversified media and entertainment company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.